Compare Payoneer Global Inc (PAYO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Pfizer Inc — how do they compare? Payoneer Global Inc trades at $7.19 (market cap $2.43B), while Pfizer Inc trades at $27.69 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 65.3× Payoneer Global Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Pfizer Inc for 158 Days on average.
| PAYO | PFE | |
|---|---|---|
Market Cap | $2.43B | $158.56B |
Volume | 1,342,701 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $7.18 | $29.02 |
52-Week Low | $4.27 | $23.67 |
Typical Hold Time | 61 Days | 158 Days |
Enterprise Value | $2.17B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.16, showing minimal daily movement with a 0.14% gain. The stock maintains a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, revenue grew to $821 million in 2025 with a 78% gross margin, but net income declined to $73 million. Recent news highlights the company's acquisition agreement with Nuvei and strategic expansion into India, while earnings show mixed quarterly performance with two misses and one beat in the last four quarters.
PAYO presents a mixed outlook with 60% analyst buy ratings supporting growth potential from international expansion and partnership renewals. However, declining profit margins, elevated P/E ratio of 51.18, and acquisition-related uncertainties pose significant risks. The stock's current technical strength contrasts with fundamental challenges, requiring careful monitoring of execution against growth initiatives.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
